FCCC LOGO Faculty Publications
Meropol NJ
Oral fluoropyrimidines in the treatment of colorectal cancer
European Journal of Cancer. 1998 Sep;34(10) :1509-1513
PMID: ISI:000076094000013   
Back to previous list
Abstract
5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since its initial development 40 years ago. Efforts to improve the therapeutic index of 5-FU have included alteration of schedule and addition of biochemical modulators. An understanding of 5-FU mechanisms of action has resulted in major therapeutic advances in the past 10 years; however, a plateau has been reached in the efficacy of 5-FU, mandating a paradigm shift for those involved in colorectal cancer drug development. One direction vigorously pursued is the development of orally administered fluoropyrimidines that maintain or improve upon the effectiveness of intravenous 5-FU. In this paper the preclinical and clinical development of oral fluoropyrimidines and their modulators is reviewed, including UFT, capecitabine, ethynyluracil and S-1. (C) 1998 Elsevier Science Ltd. All rights reserved.
Notes
Times Cited: 26 English Review 122WG EUR J CANCER